1. Home
  2. ADVB vs GANX Comparison

ADVB vs GANX Comparison

Compare ADVB & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ADVB

Advanced Biomed Inc.

HOLD

Current Price

$5.47

Market Cap

109.2M

Sector

Health Care

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$2.53

Market Cap

112.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADVB
GANX
Founded
2014
2017
Country
United States
United States
Employees
31
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
109.2M
112.7M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
ADVB
GANX
Price
$5.47
$2.53
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.20
AVG Volume (30 Days)
200.2K
683.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
47.95
EPS
N/A
N/A
Revenue
N/A
$55,180.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.26
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.19
$1.41
52 Week High
$5.82
$4.34

Technical Indicators

Market Signals
Indicator
ADVB
GANX
Relative Strength Index (RSI) 83.52 52.16
Support Level $0.36 $1.60
Resistance Level $5.75 $2.79
Average True Range (ATR) 0.53 0.23
MACD 0.06 -0.01
Stochastic Oscillator 76.73 24.11

Price Performance

Historical Comparison
ADVB
GANX

About ADVB Advanced Biomed Inc.

Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: